Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | GAPDH | P04406 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA9 | Q16790 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | NT5E | P21589 | 1/20 | 0.41 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.41 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.41 |
| ▸ | HRAS | P01112 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5717456 | 1.00 | MEN1 (0.59) | MEN1USP2POLBKMT2AGAPDH | |
| SCHEMBL7942376 | 0.95 | MEN1 (0.61) | MEN1USP2POLBKMT2AGAPDH | |
| SCHEMBL5080725 | 0.95 | MEN1 (0.61) | MEN1USP2POLBKMT2AGAPDH | |
| SCHEMBL20983914 | 0.95 | MEN1 (0.61) | MEN1USP2POLBKMT2AGAPDH | |
| SCHEMBL9002102 | 0.95 | MEN1 (0.61) | MEN1USP2POLBKMT2AGAPDH | |
| SCHEMBL9002093 | 0.95 | MEN1 (0.61) | MEN1USP2POLBKMT2AGAPDH | |
| SCHEMBL9137347 | 0.92 | MEN1 (0.55) | MEN1USP2POLBKMT2AGAPDH | |
| SCHEMBL10887852 | 0.91 | MEN1 (0.50) | MEN1USP2POLBKMT2AGAPDH | |
| SCHEMBL10887848 | 0.91 | MEN1 (0.50) | MEN1USP2POLBKMT2AGAPDH | |
| SCHEMBL30976646 | 0.90 | MEN1 (0.60) | MEN1USP2POLBKMT2AGAPDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1124565-B1 | AZIDO DERIVATIVES OF BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HIV INFECTION | CENTRE NAT RECH SCIENT (FR) | 2006-03-29 | — | — | EP | disclosed |
| EP-1124839-B1 | NUCLEOSIDES WITH ANTI-HEPATITIS B VIRUS ACTIVITY | CENTRE NAT RECH SCIENT (FR) | 2006-01-11 | — | — | EP | disclosed |
| US-6896900-B2 | β-L-2'-deoxy-nucleosides for the treatment of HIV infection | EMORY UNIVERSITY (US) | 2005-05-24 | — | — | US | disclosed |
| US-20030036528-A1 | Beta-L-2'-deoxy-nucleosides for the treatment of HIV infection | THE CENTRE NATIONAL DA LA RECHERCHE SCIENTIFIQUE | 2003-02-20 | — | — | US | disclosed |
| US-6458773-B1 | ADMINISTERING AN EFFECTIVE AMOUNT OF A .BETA.-L-(2'OR 3'-AZIDO)2',3'-DIDEOXY-5-FLUOROCYTOSINE WHEREIN R IS H, ACYL, MONOPHOSPHATE, DIPHOSPHATE, OR TRIPHOSPHATE, OR A STABILIZED PHOSPHATE DERIVATIVE (TO FORM A STABILIZED NUCLEOTIDE | EMORY UNIVERSITY | 2002-10-01 | — | — | US | disclosed |
| US-6407077-B1 | ADMINISTERING B-L-(-2*-AZIDO)-2*,3*-DIDEOXY-5-FLUOROCYTIDINE DERIVATIVE; ACQUIRED IMMUNE DEFICIENCY SYNDROMOE (AIDS) TREATMENT | EMORY UNIVERSITY | 2002-06-18 | — | — | US | disclosed |
| EP-1124839-A2 | NUCLEOSIDES WITH ANTI-HEPATITIS B VIRUS ACTIVITY | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2001-08-22 | — | — | EP | disclosed |
| EP-1124565-A1 | AZIDO DERIVATIVES OF BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HIV INFECTION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2001-08-22 | — | — | EP | disclosed |
| WO-2000025799-A1 | β-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HIV INFECTION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2000-05-11 | — | — | WO | disclosed |
| WO-2000026225-A2 | NUCLEOSIDES WITH ANTI-HEPATITIS B VIRUS ACTIVITY | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2000-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030036528-A1 | Beta-L-2'-deoxy-nucleosides for the treatment of HIV infection | DUT, SAMHD1, TYMP | MEN1 4231/4885USP2 2990/4885POLB 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.